secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001140361-25-029143
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics Q2 revenue up 29% underlying; launches yield-enhanced IG mfg
---------------------------------------------------------------------------

- Q2 2025 total revenue $122.0M, up 14% YoY (29% excluding $12.6M prior-year Medicaid reversal).
- GAAP net income $34.2M; Adjusted EBITDA $50.8M, up 59% YoY underlying.
- Began commercial-scale yield-enhanced IG manufacturing delivering 20%+ output gain.
- Closed $300M J.P. Morgan-led financing ($75M term loan, $225M revolver) replacing Ares debt.
- Reaffirmed FY2025-2026 guidance; pre-2030 revenue target $1.1B+; repurchased $15M stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/0001140361-25-029143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/ef20053140_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-029143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer